U.S. flag

An official website of the Department of Health & Human Services

AHRQ: Agency for Healthcare Research and Quality

Search AHRQ

For an exact phrase match, enclose search terms in double quotes.

Go to Advanced Search
Go to Basic Search

Results

Total Results: 258 records

Showing results for "end stage renal".

  1. 8 (pdf file)

    effectivehealthcare.ahrq.gov/sites/default/files/methodsguide_chou_assessing_harms_when_comparing.pdf
    November 01, 2008 - outcomes data, including data that showed no difference in gastrointestinal adverse events at the end … Development of instruments for assessing risk of bias specifically in studies of harms is still in an early stage … Adverse Effects of Cyclooxygenase 2 Inhibitors on Renal and Arrhythmia Events: Meta-analysis of

  2. 8 (pdf file)

    effectivehealthcare.ahrq.gov/sites/default/files/pdf/methods-guidance-harms_methods.pdf
    November 01, 2008 - outcomes data, including data that showed no difference in gastrointestinal adverse events at the end … Development of instruments for assessing risk of bias specifically in studies of harms is still in an early stage … Adverse Effects of Cyclooxygenase 2 Inhibitors on Renal and Arrhythmia Events: Meta-analysis of

  3. Abnormal-Uterine-Bleeding Executive (pdf file)

    effectivehealthcare.ahrq.gov/sites/default/files/related_files/abnormal-uterine-bleeding_executive.pdf
    March 01, 2013 - • Who are healthy, and without renal impairment, hepatic impairment, intestinal disease, thyroid

  4. Type-2-Diabetes-Medications-Update Surveillance (pdf file)

    effectivehealthcare.ahrq.gov/sites/default/files/related_files/type-2-diabetes-medications-update_surveillance.pdf
    December 31, 2013 - pioglitazone at baseline (228 mg/dl), and for placebo plus pioglitazone at baseline (236 mg/dl) and end … No clinically significant changes in renal function. … Glimepiride(sulfo nylureas) with metformin RCT 68 normoalbuminuric type 2 diabetes patients 1 year Renal … A total of 39.2 (exenatide) vs. 20.8% (insulin) of patients reached the composite end point of A1C … Yale, 201345 Canagliflozin Placebo RCT 269 subjects with type 2 diabetes and stage 3 chronic kidney

  5. Infantile-Hemangioma Executive (pdf file)

    effectivehealthcare.ahrq.gov/sites/default/files/related_files/infantile-hemangioma_executive.pdf
    January 01, 2016 - were typically not severe, only one comparative study29 had greater than 6 months followup after the end … report use of steroids and laser treatments in younger children with lesions in the proliferative stage … SACRAL syndrome: spinal dysraphism, anogenital, cutaneous, renal and urologic anomalies, associated

  6. Data-Points-7-Tables1 (xls file)

    effectivehealthcare.ahrq.gov/sites/default/files/data-points-7-tables1.xls
    August 25, 2011 - Ingredient, Age, Gender, and Race Note: A dash signifies a small cell count (less than 11); ESRD = end … stage renal disease.

  7. Data-Points-7-Tables (xls file)

    effectivehealthcare.ahrq.gov/sites/default/files/data-points-7-tables.xls
    August 25, 2011 - Ingredient, Age, Gender, and Race Note: A dash signifies a small cell count (less than 11); ESRD = end … stage renal disease.

  8. Disposition of Comments for Quality Improvement Interventions To Address Health Disparities (pdf file)

    effectivehealthcare.ahrq.gov/sites/default/files/related_files/disparities-quality-improvement_disposition-comments.pdf
    August 27, 2012 - The first use of much of this dates back 60 years or more (to the end of the WWII), so you might indicate … No papers discussing end stage renal disease or cystic fibrosis were eligible for inclusion. … depression...I think the findings are that women were receiving better care at baseline, and that by the end … The take home message from this report for me is much more like: “At this stage, and with the available

  9. Infectious Disease Including HIV/AIDS #09 (pdf file)

    effectivehealthcare.ahrq.gov/sites/default/files/infectiousdisease_hi_impact.pdf
    December 01, 2013 - Based on this input, our overall assessment is that this intervention is in the higher end of the high … Based on this input, our overall assessment is that this intervention is in the lower end of the high … users of emtricitabine/tenofovir should be monitored for potential side effects. 48 Decline in renal … Based on this input, our overall assessment is that this intervention is in the higher end of the high … Based on this input, our overall assessment is that this intervention is in the higher end of the high

  10. Data-Points-7-Tables1 (pdf file)

    effectivehealthcare.ahrq.gov/sites/default/files/data-points-7-tables1.pdf
    August 22, 2011 - Ingredient, Age, Gender, and Race Note: An asterisk (*) signifies a small cell count (less than 11); ESRD = end … stage renal disease.

  11. Data-Points-7-Tables (pdf file)

    effectivehealthcare.ahrq.gov/sites/default/files/data-points-7-tables.pdf
    August 22, 2011 - Ingredient, Age, Gender, and Race Note: An asterisk (*) signifies a small cell count (less than 11); ESRD = end … stage renal disease.

  12. App-D-Surv-Report-2-Noninvasive-Nonpharma 0 (xls file)

    effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-d-surv-report-2-noninvasive-nonpharma_0.xlsx
    January 01, 2022 - all six treatment sessions and to attend follow-up visits for at least 12 months (52 weeks) after the end … 11.69), p=NR TSK: 23.02 (6.26) vs. 25.13 (6.85), p=NR NR NR One serious adverse event occurred at the end … within each treatment arm (yoga=A1 and A2, PT=B1 and B2) did not differ in primary outcomes at the end … Recieved 12 weekly sessions of RFCBT at the end of the study. A vs. … sciatica; ongoing pregnancy; hypertension, cardiovascular disease, diabetes mellitus, liver disease, renal

  13. App-D-Surv-Report-3-Noninvasive-Nonpharma 0 (xls file)

    effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-d-surv-report-3-noninvasive-nonpharma_0.xlsx
    January 01, 2022 - all six treatment sessions and to attend follow-up visits for at least 12 months (52 weeks) after the end … 11.69), p=NR TSK: 23.02 (6.26) vs. 25.13 (6.85), p=NR NR NR One serious adverse event occurred at the end … within each treatment arm (yoga=A1 and A2, PT=B1 and B2) did not differ in primary outcomes at the end … Recieved 12 weekly sessions of RFCBT at the end of the study. A vs. … sciatica; ongoing pregnancy; hypertension, cardiovascular disease, diabetes mellitus, liver disease, renal

  14. Infectious Disease Including HIV/AIDS #09 (pdf file)

    effectivehealthcare.ahrq.gov/sites/default/files/09_infectiousdisease_potential_high_impact_june_2012.pdf
    January 01, 2012 - Based on this input, our overall assessment is that this intervention is in the higher end of the high-potential-impact … Based on this input, our overall assessment is that this intervention is in the lower end of the high-potential … Decline in renal function and proteinuria may be related to long-term use of emtricitabine/tenofovir … Based on this input, our overall assessment is that this intervention is in the higher end of the high-potential … Based on this input, our overall assessment is that this intervention is in the higher end of the high

  15. PULMONARY with "Discussions" in Exec Summary (pdf file)

    effectivehealthcare.ahrq.gov/sites/default/files/pulmonary-horizon-scan-high-impact-1506.pdf
    October 01, 2015 - Based on this input, our overall assessment is that this intervention is in the high end of the high-impact-potential … rejection, arrhythmias, BOS, narrowing of air passages, primary graft dysfunction or lung not responding, renal

  16. Disposition of Comments Report for Testing of CYP2C19 Variants and Platelet Reactivity for Guiding Antiplatelet Treatment (pdf file)

    effectivehealthcare.ahrq.gov/sites/default/files/related_files/antiplatelet-treatment_disposition-comments.pdf
    September 25, 2013 - (e.g., patients with heart failure, obesity, diabetes, acute coronary syndrome presentation, and renal … aggregation (FPA), which is related to light transmission measured at a specific time point near the end

  17. Data-Points-6-Tables (xls file)

    effectivehealthcare.ahrq.gov/sites/default/files/data-points-6-tables.xls
    January 01, 2006 - Ingredient, 2006-2009 Note: A single period (.) signifies a small cell count (less than 11); ESRD = end … stage renal disease.

  18. Data-Points-6-Tables1 (pdf file)

    effectivehealthcare.ahrq.gov/sites/default/files/data-points-6-tables1.pdf
    January 01, 2009 - Disabled/ESRD = under 65; ESRD = end stage renal disease; AI/AN = American Indian or Alaska Native
SHARE:
Facebook Twitter Print Facebook Share

Search the AHRQ Archive

Information and reports more than 5 years old may be found in the AHRQ Archive site.

Search Archive

Search Within A Specific AHRQ Site

You selected to view results for the following site:

View results from all sites